Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Autolus Therapeutics plc stock logo
AUTL
Autolus Therapeutics
$1.14
-5.8%
$1.77
$1.13
$5.41
$303.35M2.061.44 million shs2.07 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$719.85
-4.5%
$838.96
$677.09
$972.53
$682.54B0.513.37 million shs4.16 million shs
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Autolus Therapeutics plc stock logo
AUTL
Autolus Therapeutics
-5.79%-24.50%-41.24%-51.69%-77.86%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-4.23%-8.72%-12.63%-9.95%-5.43%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Autolus Therapeutics plc stock logo
AUTL
Autolus Therapeutics
2.0162 of 5 stars
3.51.00.00.01.63.30.6
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.9686 of 5 stars
4.45.03.34.02.72.51.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Autolus Therapeutics plc stock logo
AUTL
Autolus Therapeutics
3.00
Buy$9.32717.54% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.89
Moderate Buy$1,017.6741.37% Upside

Current Analyst Ratings Breakdown

Latest LLY and AUTL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/10/2025
Autolus Therapeutics plc stock logo
AUTL
Autolus Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
4/9/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$1,146.00 ➝ $1,124.00
4/8/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$892.00 ➝ $888.00
4/1/2025
Autolus Therapeutics plc stock logo
AUTL
Autolus Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$11.00 ➝ $10.00
3/21/2025
Autolus Therapeutics plc stock logo
AUTL
Autolus Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$8.00 ➝ $6.00
3/6/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$1,146.00
3/5/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$970.00 ➝ $1,100.00
2/3/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$1,029.00 ➝ $1,038.00
1/28/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$1,250.00 ➝ $1,190.00
1/28/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$1,000.00 ➝ $970.00
1/17/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$950.00
(Data available from 4/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Autolus Therapeutics plc stock logo
AUTL
Autolus Therapeutics
$10.12M29.98N/AN/A$0.64 per share1.78
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$45.04B15.15$11.74 per share61.34$15.05 per share47.83
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Autolus Therapeutics plc stock logo
AUTL
Autolus Therapeutics
-$208.38M-$0.86N/AN/AN/AN/A-63.65%-36.54%5/16/2025 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$10.59B$11.7161.4723.131.4023.51%85.24%16.19%5/1/2025 (Estimated)

Latest LLY and AUTL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2025Q1 2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$4.64N/AN/AN/A$12.77 billionN/A
3/20/2025Q4 2024
Autolus Therapeutics plc stock logo
AUTL
Autolus Therapeutics
-$0.21-$0.09+$0.12-$0.09$2.98 million$0.03 million
2/6/2025Q4 2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.45$5.32-$0.13$4.88$13.42 billionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Autolus Therapeutics plc stock logo
AUTL
Autolus Therapeutics
N/AN/AN/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.000.83%+15.21%51.24%11 Years
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Autolus Therapeutics plc stock logo
AUTL
Autolus Therapeutics
N/A
13.69
13.69
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.00
1.15
0.97

Institutional Ownership

CompanyInstitutional Ownership
Autolus Therapeutics plc stock logo
AUTL
Autolus Therapeutics
72.83%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%

Insider Ownership

CompanyInsider Ownership
Autolus Therapeutics plc stock logo
AUTL
Autolus Therapeutics
25.70%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.13%
CompanyEmployeesShares OutstandingFree FloatOptionable
Autolus Therapeutics plc stock logo
AUTL
Autolus Therapeutics
330266.09 million197.71 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
39,000948.17 million948.08 millionOptionable

Recent News About These Companies

Eli Lilly and Company stock logo
Promising Pharmaceutical Stocks To Consider - April 9th
Eli Lilly & Co (LLY) Gets a Buy from Morgan Stanley

New MarketBeat Followers Over Time

Media Sentiment Over Time

Autolus Therapeutics stock logo

Autolus Therapeutics NASDAQ:AUTL

$1.14 -0.07 (-5.79%)
Closing price 04/10/2025 04:00 PM Eastern
Extended Trading
$1.14 +0.00 (+0.09%)
As of 04/10/2025 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$719.85 -33.86 (-4.49%)
Closing price 04/10/2025 03:59 PM Eastern
Extended Trading
$717.25 -2.60 (-0.36%)
As of 04/10/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.